InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

TechMediaBreaks – BOXABL Inc. (NASDAQ: BXBL) Unveils Server Pod Concept for AI and Cloud Computing Infrastructure

October 28, 2026 — BOXABL (NASDAQ: BXBL) is exploring opportunities to apply its factory-built construction model to the growing data center market through a conceptual Server Pod design intended to house artificial intelligence and cloud-computing infrastructure. The company has outlined potential configurations ranging from compact 10-foot and 20-foot units to 40-foot enclosures and a proposed 2,500-square-foot “Server Tron.


TechMediaBreaks – Sentinel AI and Webull Launch Pilot Program to Enhance Retail Investor Engagement

October 28, 2026 — Sentinel AI and Webull (NASDAQ: BULL) announced a joint pilot program designed to help publicly traded companies engage retail investors through real-time sentiment analysis and targeted investor communications. The initiative combines Sentinel AI’s technology for monitoring bullish and bearish narratives across social media and online news with Webull’s Corporate Connect Service, which provides verified company pages within its trading platform.


NetworkNewsBreaks – Earth Science Tech Inc. (ETST) Brings AI and In-House Expertise to Enhance Operational Efficiency

October 28, 2026 — Earth Science Tech (OTCQB: ETST) is leveraging artificial intelligence (“AI”), proprietary software and its in-house IT expertise to improve operational efficiency, reduce costs and support sustainable growth across its pharmacy and telemedicine businesses. Led by Chief Technology Officer Chris Rose, the company has developed an integrated software and data platform connecting its pharmacies, curative telehealth business and My Online Consultation physician network.


New Immunotherapy Prolongs Survival of Lung Cancer Patients

October 28, 2026 — A combination of two immunotherapy drugs has significantly extended survival in patients with one of the deadliest forms of lung cancer, with trial data showing median survival nearly doubling against the current standard of care. Results from the Phase 3 study involving 563 patients were presented during a conference of the European Society for Medical Oncology in Madrid and also published simultaneously in the New England Journal of Medicine.


InvestorNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Featured in AINewsWire Editorial on AI Semiconductor Manufacturing and Automation

October 28, 2026 — Nightfood Holdings (OTCQB: NGTF), operating as TechForce Robotics, was featured in an AINewsWire editorial examining growing demand for semiconductor manufacturing equipment and automated inspection technologies amid expanding artificial intelligence (“AI”) infrastructure investment. The editorial highlights Nightfood’s recent acquisition of designs, technology and expertise for automated optical inspection (“AOI”) equipment used in chip-on-wafer-on-substrate (“CoWoS”) advanced semiconductor packaging.


NetworkNewsBreaks – VolitionRx (NYSE American: VNRX) Signs LOI With Missionpharma to Explore Global Development and Commercialization of NETosis Diagnostic Test

October 28, 2026 — VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that it has signed a nonbinding letter of intent (“LOI”) with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology (“LFT”) for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings.


BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Progress in Phase IIA Ebola Treatment Trial of NV-387 Oral Gummies

October 27, 2026 — NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus disease in the Democratic Republic of Congo (“DRC”) is progressing, with advancement to Phase IIB anticipated following completion of the initial study phase.


OpenAI Reveals its Agents Deactivated Their Controls During Tests

October 27, 2026 — OpenAI has disclosed two cases where AI agents using its models interfered with in-house monitoring protections while undertaking assigned programming roles. In one incident, an AI agent disabled security alerts, while another disabled a monitoring component and later gave an inaccurate account of what it had done.